Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Sellas Life Sciences Group Inc    SLS

SELLAS LIFE SCIENCES GROUP INC

(SLS)
  Report  
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
04/11/2019 04/12/2019 04/15/2019 04/16/2019 04/17/2019 Date
1.07(c) 1.04(c) 1.03(c) 1.02(c) 0.99(c) Last
294 872 251 544 249 187 455 786 265 373 Volume
-3.60% -2.80% -0.96% -0.97% -2.94% Change
More quotes
Financials (USD)
Sales 2019 -
EBIT 2019 -20,7 M
Net income 2019 -23,3 M
Debt 2019 -
Yield 2019 -
Sales 2020 -
EBIT 2020 -26,6 M
Net income 2020 -29,1 M
Debt 2020 -
Yield 2020 -
P/E ratio 2019 -
P/E ratio 2020
Capi. / Sales2019 0
Capi. / Sales2020 0
Capitalization 22,9 M
More Financials
Company
SELLAS Life Sciences Group, Inc., formerly Galena Biopharma, Inc., is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company's development portfolio ranges from mid- to late-stage clinical... 
Sector
Pharmaceuticals
Calendar
-
More about the company
Latest news on SELLAS LIFE SCIENCES GROUP
04/04SELLAS Life Sciences Group and World-Renowned Cancer Center to Study Galinpep..
GL
03/22SELLAS LIFE SCIENCES GROUP, INC. : Results of Operations and Financial Condition..
AQ
03/22SELLAS Life Sciences Reports 2018 Financial Results and Provides Business Upd..
GL
03/22SELLAS LIFE SCIENCES : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITI..
AQ
03/06SELLAS LIFE SCIENCES GROUP, INC. : Entry into a Material Definitive Agreement, U..
AQ
03/04SELLAS Life Sciences Announces Presentation of Final Data Analysis from Phase..
GL
02/26SELLAS LIFE SCIENCES GROUP, INC. : Other Events, Financial Statements and Exhibi..
AQ
02/26SELLAS Life Sciences Announces Review of Strategic Alternatives
GL
02/12SELLAS Life Sciences Provides Galinpepimut-S and Nelipepimut-S Program Update
GL
01/31SELLAS Life Sciences to Present at the 2019 BIO CEO & Investor Conference
GL
More news
Sector news : Pharmaceuticals - NEC
04/17ACREAGE : Canopy Growth nearing deal to buy U.S.-based pot company Acreage Holdi..
RE
04/17MERCK AND : on Pace for Largest Percent Decrease in Over a Year -- Data Talk
DJ
04/17Roche Raises 2019 Sales View After 1Q Sales Beat
DJ
04/17SPARK THERAPEUTICS : Swiss drugmaker Roche ups outlook as sales growth offsets p..
RE
04/17SPARK THERAPEUTICS : Swiss drugmaker Roche ups outlook as sales growth offsets p..
RE
More sector news : Pharmaceuticals - NEC
Chart SELLAS LIFE SCIENCES GROUP INC
Duration : Period :
Sellas Life Sciences Group Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SELLAS LIFE SCIENCES GROUP
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 8,75 $
Spread / Average Target 784%
EPS Revisions
Managers
NameTitle
Angelos M. Stergiou President, Chief Executive Officer & Director
Jane Wasman Independent Chairman
John T. Burns Chief Accounting Officer, VP-Finance & Controller
Nicholas J. Sarlis Chief Medical Officer & Executive Vice President
John W. Varian Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
SELLAS LIFE SCIENCES GROUP INC-19.51%23
JOHNSON & JOHNSON6.95%368 847
ROCHE HOLDING LTD.9.41%227 539
PFIZER-6.25%221 406
NOVARTIS5.99%199 282
MERCK AND COMPANY-3.26%190 941